These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36938401)
1. Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities. Hossain MS; Jahan S; Al Rezwan Rahman S; Rahman M; Kumar D; Paul S; Chandra Rajbangshi J Heliyon; 2023 Mar; 9(3):e14259. PubMed ID: 36938401 [TBL] [Abstract][Full Text] [Related]
2. Optimization of empagliflozin immediate release tablets (10 mg) using central composite rotatable design with response surface methodology. M Hanif A; Bushra R; Iffat W; Ghayas S; Perveen S; Riaz H; Alam S; Ali SI; Ismail NE; Un-Nisa Z Pak J Pharm Sci; 2021 Jul; 34(4(Supplementary)):1519-1525. PubMed ID: 34799327 [TBL] [Abstract][Full Text] [Related]
3. Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies. Kang SJ; Kim JE Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111730 [TBL] [Abstract][Full Text] [Related]
4. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression. Tafere C; Yilma Z; Abrha S; Yehualaw A PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014 [TBL] [Abstract][Full Text] [Related]
5. Development of extended-release metformin core tablet and synergistic coating of sitagliptin for the treatment of type-II diabetes mellitus - A comparative drug release evaluation with reference product. Ahmed A; Wasim AA; Fazal-Ur-Rehman S; Ali M Pak J Pharm Sci; 2022 Sep; 35(5):1473-1480. PubMed ID: 36451578 [TBL] [Abstract][Full Text] [Related]
6. Disintegrants combination: development and optimization of a cefadroxil fast disintegrating tablet. Rahim N; Naqvi SB; Bibi R; Iffat W; Shakeel S; Muhammad IN Pak J Pharm Sci; 2014 Sep; 27(5 Spec no):1467-75. PubMed ID: 25176230 [TBL] [Abstract][Full Text] [Related]
7. Formulation development of chewable albendazole tablets with improved dissolution rate. Kimaro E; Tibalinda P; Shedafa R; Temu M; Kaale E Heliyon; 2019 Dec; 5(12):e02911. PubMed ID: 31890938 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878 [TBL] [Abstract][Full Text] [Related]
9. Formulation Optimization and Assessment of Dexamethasone Orally Disintegrating Tablets Using Box-Behnken Design. Soroush H; Ghorbani-Bidkorbeh F; Mortazavi SA; Mehramizi A Iran J Pharm Res; 2018; 17(4):1150-1163. PubMed ID: 30568675 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550 [TBL] [Abstract][Full Text] [Related]
11. Optimization study on the formulation of roxithromycin dispersible tablet using experimental design. Weon KY; Lee KT; Seo SH Arch Pharm Res; 2000 Oct; 23(5):507-12. PubMed ID: 11059832 [TBL] [Abstract][Full Text] [Related]
12. Optimized furosemide taste masked orally disintegrating tablets. Ibrahim MA; Abou El Ela AESF Saudi Pharm J; 2017 Nov; 25(7):1055-1062. PubMed ID: 29158715 [TBL] [Abstract][Full Text] [Related]
13. Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance. Jahangir MA; Khan R; Sarim Imam S Artif Cells Nanomed Biotechnol; 2018; 46(sup1):66-78. PubMed ID: 29226729 [TBL] [Abstract][Full Text] [Related]
14. DESIGN AND IN VITRO EVALUATION OF ACRIVASTINE AS ORODISPERSIBLE TABLET USING DIRECT COMPRESSION METHOD. Naji GH; Al-Zheery WH; Fareed NY Wiad Lek; 2023; 76(1):170-174. PubMed ID: 36883506 [TBL] [Abstract][Full Text] [Related]
15. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients. Babar M; Hussain M; Ahmad M; Akhtar L J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. Ahmed I; Raja UY; Wahab MU; Rehman T; Ishtiaq O; Aamir AH; Ghaffar T; Raza A; Kumar S; Sherin A; Masood F; Randhawa FA; Asghar A; Khan S BMC Endocr Disord; 2022 Oct; 22(1):247. PubMed ID: 36224542 [TBL] [Abstract][Full Text] [Related]
17. Formulation optimization study for an immediate-release tablet. Kyriacos S; Dimassi H Int J Pharm Compd; 2009; 13(3):259-61. PubMed ID: 23966482 [TBL] [Abstract][Full Text] [Related]
18. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982 [TBL] [Abstract][Full Text] [Related]
19. Influence of sodium starch glycolate, croscarmellose sodium and crospovidone on disintegration and dissolution of stevia-loaded tablets. Yousaf AM; Naheed F; Shahzad Y; Hussain T; Mahmood T Polim Med; 2019; 49(1):19-26. PubMed ID: 31756060 [TBL] [Abstract][Full Text] [Related]
20. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin. Manaer T; Yu L; Zhang Y; Xiao XJ; Nabi XH J Ethnopharmacol; 2015 Jul; 169():269-74. PubMed ID: 25922265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]